The potential commercialization of neuronal replacement therapy using smart polymers

Abstract

NeuroBioChip Device is a programmable, biocompatible, biodegradable, polymer matrix which allows the growth and programming of donor neurons. It creates a microenvironment conducive for neuronal outgrowth and promises a novel cure for neurological disorders caused by localized sites of brain damage, such as Parkinson's disease, stroke, and spinal injury. This chip is being researched in the MIT laboratories of Drs. Robert Langer and Mriganka Sur. My thesis addresses the challenges and possible strategies in commercializing this technology. The need for this treatment was evaluated in the context of current therapies available for the treatment of relevant neurological disorders. Extensive field interviews were conducted. Among other factors, the varying clockspeeds between different components of the device, the unsustainable cost structure and the emerging status of complementary technologies suggested that the development of the therapy is best pursued in collaboration with a large biopharmaceutical or medical device firm.